文献速递银屑病与炎症性皮肤病

比美吉珠单抗在中重度斑块状银屑病患者中的安全性:2期和3期随机临床试验汇总结果

Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
PubMed 文献 · JAMA Dermatol · 2022-01-01

该研究汇总了8项2期和3期随机临床试验中1789例接受比美吉珠单抗治疗的中重度斑块状银屑病患者的2年安全性数据。总体暴露量为3109.7人年,治疗中出现的不良事件发生率为202.4/100人年,且未随暴露时间延长而增加。最常见不良事件为鼻咽炎、口腔念珠菌病和上呼吸道感染,多数口腔念珠菌病为轻中度;炎症性肠病、自杀意念和行为及主要不良心血管事件发生率低。结论认为比美吉珠单抗耐受性良好,除轻中度口腔念珠菌病发生率增加外,未观察到新的安全性信号。

要点

  • 比美吉珠单抗治疗中重度斑块状银屑病2年安全性汇总显示总体耐受性良好。
  • 治疗中出现的不良事件发生率为202.4/100人年,未随暴露时间延长而增加。
  • 最常见不良事件为鼻咽炎、口腔念珠菌病和上呼吸道感染,多数口腔念珠菌病为轻中度。

核心结论

  • 在这项纳入8项随机临床试验患者队列的汇总分析中,比美吉珠单抗耐受性良好,除轻中度口腔念珠菌病发生率增加外,未观察到新的安全性信号,且不良事件风险未随暴露时间延长而增加。

研究设计与样本

  • 汇总4项2期随机临床试验(BE ABLE 1、BE ABLE 2、PS0016和PS0018)和4项3期随机临床试验(BE VIVID、BE READY、BE SURE和BE BRIGHT)的安全性数据,纳入2年研究治疗期。
  • 纳入对象为符合全身性银屑病治疗和/或光疗条件的成人中重度斑块状银屑病患者,银屑病面积和严重程度指数≥12、受累体表面积≥10%、研究者全球评估评分在5分量表上≥3。
  • 共1789例患者(1252例[70.0%]男性;平均[标准差]年龄45.2[13.5]岁)接受1次或以上比美吉珠单抗治疗并纳入分析;比美吉珠单抗总暴露量为3109.7人年。

主要发现

  • 治疗中出现的不良事件发生率为202.4/100人年,且未随比美吉珠单抗暴露时间延长而增加。
  • 报告最频繁的3种治疗中出现的不良事件为鼻咽炎(19.1/100人年;95%CI 17.4-20.9/100人年)、口腔念珠菌病(12.6/100人年;95%CI 11.3-14.0/100人年)和上呼吸道感染(8.9/100人年;95%CI 7.8-10.1/100人年)。
  • 多数口腔念珠菌病事件为轻中度;3例事件导致停药。
  • 炎症性肠病发生率为0.1/100人年(95%CI 0.0-0.3/100人年),经裁定的自杀意念和行为发生率为0.0/100人年(95%CI 0.0-0.2/100人年),经裁定的主要不良心血管事件发生率为0.5/100人年(95%CI 0.3-0.8/100人年)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Psoriasis is a chronic disease requiring long-term management; understanding the long-term safety profiles of psoriasis treatments, such as bimekizumab, is important. OBJECTIVE: To evaluate the 2-year safety profile of bimekizumab in patients with moderate to severe plaque psoriasis. DESIGN, SETTING, AND PARTICIPANTS: Safety data were pooled from a cohort of patients from 4 phase 2 randomized clinical trials (BE ABLE 1, BE ABLE 2, PS0016, and PS0018) and 4 phase 3 randomized clinical trials (BE VIVID, BE READY, BE SURE, and BE BRIGHT) to include 2 years of study treatment. Data were obtained on adults with moderate to severe plaque psoriasis (Psoriasis Area and Severity Index level ≥12, ≥10% body surface area affected by psoriasis, and an Investigator's Global Assessment score ≥3 on a 5-point scale) who were eligible for systemic psoriasis therapy and/or phototherapy. INTERVENTIONS: Included patients received 1 or more doses of bimekizumab during the phase 2 or phase 3 trials. MAIN OUTCOMES AND MEASURES: Treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAEs leading to treatment discontinuation are reported using exposure-adjusted incidence rates (EAIRs) per 100 person-years. RESULTS: A total of 1789 patients (1252 [70.0%] men; mean [SD] age, 45.2 [13.5] years) were treated with 1 or more doses of bimekizumab across the phase 2/3 trials and were included in these analyses; total bimekizumab exposure was 3109.7 person-years. TEAEs occurred at an EAIR of 202.4 per 100 person-years and did not increase with longer duration of bimekizumab exposure. The 3 most frequently reported TEAEs were nasopharyngitis (19.1 per 100 person-years; 95% CI, 17.4-20.9 per 100 person-years), oral candidiasis (12.6 per 100 person-years; 95% CI, 11.3-14.0 per 100 person-years), and upper respiratory tract infection (8.9 per 100 person-years; 95% CI, 7.8-10.1 per 100 person-years). Most oral candidiasis events were mild or moderate; 3 events led to discontinuation. The EAIRs of inflammatory bowel disease (0.1 per 100 person-years; 95% CI, 0.0-0.3 per 100 person-years), adjudicated suicidal ideation and behavior (0.0 per 100 person-years; 95% CI, 0.0-0.2 per 100 person-years), and adjudicated major adverse cardiac events (0.5 per 100 person-years; 95% CI, 0.3-0.8 per 100 person-years) were low. CONCLUSIONS AND RELEVANCE: In these pooled analyses of data from a cohort of patients from 8 randomized clinical trials, bimekizumab was well tolerated aside from an increased incidence of mild to moderate oral candidiasis. No safety signals were observed compared with previous reports, and there was no increased risk of AEs with longer duration of bimekizumab exposure.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Gordon KB, Langley RG, Warren RB, et al. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2022. PMID: 35544084. doi:10.1001/jamadermatol.2022.1185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。